Nordic Capital Fund IX (“Nordic Capital”) today announced the signing of the acquisition of Ober Scharrer Group (“OSG” or “the Group”). OSG is Germany’s largest provider for treatments for major causes of blindness and visual impairment as well as non-invasive treatments and diagnosis of eye disorders.
OSG, founded in 1982 and headquartered in Fürth, Germany, offers a broad spectrum of specialised ophthalmic treatments and provides high quality medical care to both public and private patients. Key services provided are surgical treatments such as cataract operations and Intravitreal Operative Drug Application (IVOM) for degenerative eye disorders. The Group has 900 employees performing more than 85,000 treatments per year across its c. 80 clinics in Germany.
As a leading healthcare investor with a 25-year track record of building high quality, sustainable healthcare businesses, Nordic Capital intends to support and further develop Ober Scharrer in line with its current strategy.
“The opportunity for future growth in the fragmented ophthalmic outpatient market is extensive and we are excited about the prospects as we continue to build our business. With Nordic Capital we have found a partner and owner that share our dedication to medical excellence, patient satisfaction and quality of services as well as our vision for growth. We believe Nordic Capital’s extensive experience in healthcare, both in and outside Germany, will be very valuable in the years to come,” comments Sibylle Stauch-Eckmann, CEO of OSG.
“Nordic Capital has followed this sector for several years, observing how OSG has continued to build its strong position and reputation for delivering medical excellence. Nordic Capital looks forward to investing in and supporting OSG’s further development and growth in its field of expertise where we see a strong demand for specialised, high quality centres to provide treatments,” says Joakim Lundvall, Partner at the Advisor to the Nordic Capital Funds.
With the acquisition of OSG from Palamon Capital Partners, Nordic Capital continues to build its healthcare franchise in the German speaking region. Since inception, the Nordic Capital Funds have invested in over 20 healthcare platforms across Europe and the USA.
The parties have agreed to not disclose the financial details. The transaction is subject to customary regulatory approvals.
Katarina Janerud, Communications Manager
Advisor to the Nordic Capital Funds
Tel: +46 8 440 50 50
About Ober Scharrer Group
The Ober Scharrer Group was established in 1982 by two physicians Dr Ober and Dr Scharrer. Headquartered in Fürth, the company now has c. 80 facilities across Germany, 900 employees and delivers more than 85,000 treatments per year. Key group services include cataract operations and Intravitreal Operative Drug Application (IVOM) for degenerative eye disorders, as well as non-invasive eye treatments and the diagnosis of eye disorders. For more information on the Ober Scharrer Group refer to www.osg.de
About Nordic Capital
Nordic Capital is a leading private equity investor in the Nordic region with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services, Industrial Goods & Services and Consumer & Retail, and key regions are the Nordics, Northern Europe, and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 12 billion in close to 100 investments. The Nordic Capital Funds are based in Jersey and are advised by advisory entities, which are based in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital, please visit www.nordiccapital.com